EGFR and non-small cell lung carcinoma: Our study results indicated that in patients with NSCLC of EGFR-sensitizing mutation with de novo BM, erlotinib provided better PFS than afatinib or gefitinib but comparable OS as afatinib or gefitinib if the patients had poor prognostic MR characteristics of BM, including tumor necrosis, rim enhancement and specific tumor locations (frontal lobe, putamen and cerebellum).